Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 442 results for cardiovascular disease

  1. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  2. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    susceptibility, environmental factors or age-related factors such as cardiovascular disease. Hearing loss may cause dementia either...

  3. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  4. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  5. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.

  6. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (HTG460)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a device under the skin of the chest, which detects and treats fast heartbeats called tachyarrhythmias.

  7. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  8. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  9. Targeted-release budesonide for treating primary IgA nephropathy (TA1128)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  10. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  11. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

  12. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

  13. Pulsed-field ablation for atrial fibrillation (HTG755)

    Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.

  14. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  15. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.